‘Historically Boston was a very insular market’, says Andrew Sucoff, chair of Goodwin’s Boston office, told Legal Business. ‘There weren’t a lot of lateral moves. That was true across the industry, but it was particularly true in Boston. There are 44 colleges and universities in the greater Boston area, as well as 22 full-service inpatient hospitals. We have the Route 128 corridor, which is called the Silicon Valley of the East, so we also have an incredible Tech sector.' Goodwin Life Sciences chair Mitch Bloom expands: ‘The life sciences sector – particularly in Boston – has been navigating a period of short-term uncertainty. Factors like reduced research funding, leadership transitions at the FDA, and proposed federal drug pricing reforms have all contributed to a more cautious investment climate. Additionally, the recent administration’s stance on tariffs and vaccine regulation could potentially further complicate the life sciences landscape.’